TAK-243

Ubiquitin-activating enzyme E1 inhibitor TAK-243 · Takeda Pharmaceutical Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TAK-243, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Studying TAK-243 in Patients With Advanced Cancer [Phase 1]